A phase II study of nilotinib, a novel tyrosine kin ase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy.

被引：1

作者：

Giles, Francis

le Coutre, Philipp

Bhalla, Kapil

Rosti, Gianantonio

Ossenkopplele, G. J.

Alimena, Giuliana

Weitzman, Aaron

Rafferty, Teresa

Zheng, Ming

Kantarjian, Hagop

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

[2] Campus Virchow Klin, Berlin, Germany

[3] H Lee Moffitt Canc Ctr, Tampa, FL USA

[4] Univ Bologna Policlin, Azienda Osped, Bologna, Italy

[5] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[6] Univ Roma La Sapienza, Azienda Policlin Umberto, Rome, Italy

[7] Novartis Pharmaceut, E Hanover, NJ USA

来源：

关键词：

D O I：

10.1182/blood.V108.11.2170.2170

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2170

引用

页码：615A / 616A

页数：2